Sun Pharma Announces Phase 2 Trial Results for SCD-044: Primary Endpoint Not Met

Unknown Apr 02, 2026 1,150 Views

Sun Pharmaceutical Industries Ltd has announced the topline results from its Phase 2 clinical trial evaluating SCD-044, a novel orally bioavailable sphingosine-1-phosphate (S1P) receptor 1 agonist, in patients with moderate to severe plaque psoriasis. The company confirmed that the trial did not...